

1 **Title:** Antibody avidity maturation favors SARS-CoV-2 convalescents over vaccinated
2 individuals granting breadth in neutralizability and tolerance against variants

3 **Authors:** Yu Nakagama,^{a,b} Katherine Candray,^{a,b,c} Natsuko Kaku,^{a,b} Yuko Komase,^d Maria-
4 Virginia Rodriguez-Funes,^e Rhina Dominguez,^f Tomoya Tsuchida,^g Hiroyuki Kunishima,^h
5 Etsuko Nagai,ⁱ Eisuke Adachi,ⁱ Dieudonné Mumba Ngoyi,^j Mari Yamasue,^k Kosaku Komiya,^k
6 Kazufumi Hiramatsu,^k Naoto Uemura,^k Yuki Sugiura,^l Mayo Yasugi,^{m,n,o} Yuka Yamagishi,^p
7 Hiroshige Mikamo,^p Satoshi Shiraishi,^q Takehiro Izumo,^r Sachie Nakagama,^{a,b} Chihiro
8 Watanabe,^{a,b} Yuko Nitahara,^{a,b} Evariste Tshibangu-Kabamba,^{a,b} Hiroshi Kakeya,^{b,s}
9 Yasutoshi Kido^{a,b}

10 **Author institutional affiliations:**

11 ^aDepartment of Virology & Parasitology, Graduate School of Medicine, Osaka Metropolitan
12 University, Osaka, Japan

13 ^bResearch Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka
14 Metropolitan University, Osaka, Japan

15 ^cCentro Nacional de Investigaciones Científicas de El Salvador (CICES), San Salvador, El
16 Salvador

17 ^dDepartment of Respiratory Internal Medicine, St. Marianna University, Yokohama Seibu
18 Hospital, Yokohama, Japan

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

19 ^e National Rosales Hospital, San Salvador, El Salvador

20 ^f El Salvador National Institute of Health, San Salvador, El Salvador

21 ^g Division of General Internal Medicine, St. Marianna University School of Medicine,
22 Kawasaki, Japan

23 ^h Department of Infectious Diseases, St. Marianna University School of Medicine,
24 Kawasaki, Japan

25 ⁱ Department of Infectious Diseases and Applied Immunology, Institute of Medical Science,
26 The University of Tokyo, Tokyo, Japan

27 ^j Institut National de Recherche Biomedicale, Kinshasa, Democratic Republic of the Congo

28 ^k Department of Respiratory Medicine and Infectious Diseases, Oita University Faculty of
29 Medicine, Oita, Japan

30 ^l Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School
31 of Medicine, Kyoto, Japan

32 ^m Graduate School of Veterinary Science, Osaka Metropolitan University, Osaka, Japan

33 ⁿ Asian Health Science Research Institute, Osaka Metropolitan University, Osaka, Japan

34 ^o Osaka International Research Center for Infectious Diseases, Osaka Metropolitan
35 University, Osaka, Japan

36 ^p Department of Clinical Infectious Diseases, Aichi Medical University, Aichi, Japan

37 ^q Department of Respiratory Medicine, Osaka City Juso Hospital, Osaka, Japan

38 ^r Department of Respiratory Medicine, Japanese Red Cross Medical Center, Tokyo, Japan

39 ^s Department of Infection Control Science, Graduate School of Medicine, Osaka
40 Metropolitan University, Osaka, Japan

41 **Keywords:** SARS-CoV-2, Antibody maturation, Avidity, Neutralization breadth, Variants of
42 concern

43 **Running title:** High-avidity SARS-CoV-2 IgG protectivity

44 **Address for correspondence (alternate):**

45 Yasutoshi Kido, MD, PhD (Yu Nakagama, MD, PhD)

46 Department of Parasitology, Graduate School of Medicine, Osaka Metropolitan University,
47 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan

48 E-mail: kidoyasu@omu.ac.jp (nakagama.yu@omu.ac.jp)

49 **Type of manuscript**

50 Major article

51

52 **Abstract**—word count 246

53 Background

54 The durability and cross-neutralizability of protective antibodies against evolving SARS-
55 CoV-2 variants are primary concerns in mitigating (re-)exposures. The role of antibody
56 maturation, the process whereby selection of higher avidity antibodies augments host
57 immunity, to determine SARS-CoV-2 neutralizability was investigated.

58 Methods

59 Sera collected from SARS-CoV-2 convalescent individuals at 2- or 10-months after
60 recovery, and BNT162b2 vaccine recipients at 3 or 25 weeks post-vaccination, were
61 analyzed. Anti-spike IgG avidity was measured on a urea-treated ELISA platform.
62 Neutralizing ability of antibodies was assessed by surrogate virus neutralization. Fold
63 change between variant and wild-type antigen neutralizability was calculated to infer
64 breadth of neutralizability.

65 Results

66 Compared with early-convalescence, the avidity index of late-convalescent sera was
67 significantly higher (median 37.7 (interquartile range 28.4–45.1) vs. 64.9 (57.5–71.5), $p <$
68 0.0001), indicative of progressive antibody maturation extending months beyond acute-
69 phase illness. The urea-resistant, high-avidity fraction of IgG was best predictive of

70 neutralizability (Spearman's $r = 0.49$ vs. 0.67 for wild-type; 0.18 – 0.52 vs. 0.48 – 0.83 for
71 variants). Higher-avidity convalescent sera showed greater cross-neutralizability against
72 SARS-CoV-2 variants ($p < 0.001$ for Alpha; $p < 0.01$ for Delta and Omicron). Vaccinees
73 experienced delayed maturation kinetics, translating to limited breadth of neutralizability at
74 week-25 post-vaccination which was only comparable to that of early-convalescence.

75 Conclusions

76 Avidity maturation grants broader neutralizability that is resilient against emerging SARS-
77 CoV-2 variants. With immunopotentialization through repeat vaccinations becoming a pivotal
78 strategy to accomplish herd immunity, understanding the variable longitudinal evolutions of
79 the two building blocks of 'hybrid immunity' is crucial.

80

81 **Text**—word count 2993

82 **Introduction**

83 Given the reported coronavirus disease 2019 (COVID-19) re-infections and
84 vaccine breakthrough infections, it is unlikely that convalescent or vaccinated individuals
85 will attain lifelong immune protection [1,2]. Therefore, the magnitude of partial immunity
86 those individuals acquire is an important issue. In the convalescent phase and thereafter,
87 circulating levels of neutralizing IgG that target the SARS-CoV-2 receptor binding domain
88 (RBD) are highly correlated with residual protectivity [3,4]. However, the durability of anti-
89 spike IgGs and their potential cross-neutralizability against rapidly evolving severe acute
90 respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are primary concerns in
91 mitigating future re-exposures [5].

92 Avidity maturation is the biological process whereby antigen-driven selection of
93 higher affinity antibodies augments the host's long-lasting protective immunity. Continuous
94 antigen presentation at germinal centers promotes the fine-tuning of the antibody's
95 complementarity toward the epitope. The kinetics and potential implications of maturing
96 antibody avidity in the context of immune protection against SARS-CoV-2 and its emerging
97 variants of concern (VOCs) remains to be fully elucidated [6–8]. In the present study, we
98 correlated the kinetics of serum antibody avidity maturation, which followed SARS-CoV-2

99 natural infections, as well as vaccine administrations, to the magnitude and breadth of *in*
100 *vitro* neutralizability. Our observations provide a logical perspective on the variable
101 durability and resilience of the two building blocks needed for the acquisition of 'hybrid
102 immunity'.

103

104 **Materials and Methods**

105 **Human subjects and sample collection**

106 Total 462 convalescent individuals, who had recovered from COVID-19 [9], were
107 recruited at Osaka Metropolitan University and collaborating institutions preceding the
108 emergence of the SARS-CoV-2 VOCs, comprising a mixed cohort from different regions,
109 where the predominant genotypes belonged to B.1 or B.1.1 lineages [10,11]. Serum
110 samples from recipients of the BNT162b2 SARS-CoV-2 mRNA vaccine were collected at
111 week 3 and week 25 after the first dose. Analyses were conducted in accordance with the
112 1964 Declaration of Helsinki and its later amendments. This research was approved by the
113 Ethical Committee of Osaka Metropolitan University Graduate School of Medicine (#2020-
114 003). All participants provided written informed consent prior to enrollment.

115

116 **Anti-spike IgG measurement**

117 Abbott SARS-CoV-2 IgG II Quant assays (Abbott, IL, USA, 6S6023) were run in
118 accordance with the manufacturer's instructions. Anti-SARS-CoV-2 IgG enzyme-linked
119 immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany, EI 2606–9601) was
120 performed in accordance with the manufacturer's instructions.

121

122 **Avidity ELISA**

123 Serum samples were tested for their avidity towards the SARS-CoV-2 spike
124 antigen using an ELISA-based assay (Euroimmun, Lübeck, Germany, EI 2606–9601) [12].
125 Samples were processed, in an extra pair of wells, with additional urea treatment (5.5 M for
126 10 min at 37°C) following the incubation of the spike antigen-coated plate with serum
127 samples, to detach any low-avidity antibodies. The avidity index (AI) was calculated as
128 follows: $AI = \frac{\{(OD_{450} \text{ of sample with } 5.5 \text{ M urea}) - (OD_{450} \text{ of negative control with } 5.5 \text{ M}$
129 $\text{urea})\}}{\{(OD_{450} \text{ of sample without urea}) - (OD_{450} \text{ of negative control without urea})\}} \times 100$
130 [%]. Serum samples were diluted 1:101 for analysis, except for the post-vaccine sera,
131 which required a higher dilution of 1:201 to bring the OD_{450} signals into linear range.

132

133 **Neutralizing ability**

134 Neutralizing ability against wild-type (WT) and VOC SARS-CoV-2 was quantified

135 using the GenScript SARS-CoV-2 sVNT (GenScript, Piscataway, NJ, USA, L00847-A), a
136 competition ELISA-based surrogate virus neutralization test (sVNT). Obtained signals have
137 been shown to strongly correlate with the results of the conventional live-virus
138 neutralization test [13,14]. The assay protocol followed that of the manufacturer's
139 instructions. Serum samples and controls were pre-incubated to neutralize WT RBD (WT;
140 GenScript, Z03594), or B.1.1.7 (Alpha; GenScript, Z03595), B.1.617.2 (Delta; GenScript,
141 Z03614), or B.1.1.529 (Omicron; GenScript, Z03730) RBD variants conjugated with
142 horseradish peroxidase. The inhibition rate (%inhibition) was calculated as
143 follows: %inhibition = $\{1 - (\text{OD}_{450} \text{ of sample}) / (\text{OD}_{450} \text{ of negative control})\} \times 100$ [%].

144

145 **Breadth of neutralizability**

146 For quantitative assessment of the serum antibodies' abilities to cross-neutralize
147 SARS-CoV-2 and its variants, the sVNT %inhibition values were converted to the linearly
148 scaled WHO International Standard units, IU/mL [15,16]. We obtained a standard inhibitory
149 dose-response curve by fitting the log-transformed IU/mL concentration values and their
150 corresponding %inhibition data, obtained from testing four-fold serially diluted WHO
151 International Standard (20/136) in the sVNT, to a four-parameter logistic equation
152 (GraphPad Prism, version 9). The neutralizing titer (IU/mL) of the participants' serum

153 samples, tested at optimized dilutions (up to 1:30, adjusted to bring the OD₄₅₀ signals into
154 quantitative range of the standard curves), was converted from sVNT %inhibition data by
155 interpolation from the standard curve per different RBD antigen. The fold changes in
156 neutralizing titer between the VOCs and WT (NT_{Alpha}/NT_{WT}, NT_{Delta}/NT_{WT}, and
157 NT_{Omicron}/NT_{WT}) were calculated to serve as the index for the 'breadth of neutralizability'.
158 Similar indices have served as quantitative measures of relative neutralizing potency
159 towards VOC strains [17].

160

161 **Statistical analysis**

162 Differences in titer, avidity, and the magnitude/breadth of neutralizing ability of
163 sera were tested by Mann-Whitney test. For the longitudinal anti-spike IgG titer plot, a
164 linear fit was performed, and Pearson's correlation coefficient was calculated. Spearman's
165 correlation coefficient was calculated to assess the strength of the correlation between
166 antibody titer and *in vitro* neutralizability. P-values less than 0.05 were considered
167 statistically significant.

168

169 **Results**

170 **Serum anti-SARS-CoV-2 antibodies decay, while maturing in avidity, over time**

171 As recurrently reported, serum levels of circulating anti-spike IgG showed
172 longitudinal decline in titer in SARS-CoV-2 convalescent individuals (Figure 1, panel A,
173 Pearson's $r = -0.28$, $p = 0.049$) [18]. To further investigate the qualitative evolution of serum
174 antibodies, representative subsets of sera matched by their total anti-spike IgG titers
175 (Figure 1, panel B, median OD₄₅₀ 1.12 (IQR 0.93–1.25) vs. 1.09 (IQR 0.89–1.26), $p = 0.98$)
176 were selected from early- and late-convalescent ($n = 29$, median 8 (IQR 7–9) weeks and n
177 = 26, median 37 (IQR 36–40) weeks post-onset of symptoms, respectively) phases, and
178 compared of their serum antibody avidity characteristics. Polyclonal antibodies present in
179 the late-convalescent sera were more avid against the SARS-CoV-2 spike antigen, and
180 thus their OD₄₅₀ were relatively resistant to urea treatment (Figure 1, panel B). The
181 difference in maturity of convalescent sera was reflected in the avidity index (AI), with that
182 of late-convalescent sera demonstrating higher AIs (Figure 1, panel C, median AI 37.7 (IQR
183 28.4–45.1) vs. 64.9 (IQR 57.5–71.5), $p < 0.0001$), indicating a progressive maturation
184 process that extends months beyond the acute phase of COVID-19.

185

186 **Higher-avidity antibodies exert broadened neutralizability against VOCs**

187 Next, we investigated the functional consequences of enhanced antibody avidity.
188 Compared with the raw OD₄₅₀ values (Figure 2, panel A, upper), the urea-resistant OD₄₅₀

189 signals from the avidity ELISA (Figure 2, panel A, lower) better correlated with the inhibition
190 rate (%inhibition) obtained from the surrogate sVNT. The results indicated a central role for
191 high-affinity anti-spike IgG antibodies in determining *in vitro* neutralizability against SARS-
192 CoV-2 WT and variant RBDs.

193 We next tested the hypothesis that serum antibody avidity determines the
194 tolerability against RBD variations. As previously reported, the Alpha, Delta, and Omicron
195 variants were more resistant to neutralization by convalescent sera, showing attenuated
196 inhibition rates in the sVNT (Figure 2, panel B). To further compare the cross-neutralizability
197 of individual sera against different VOCs, in other words the ‘breadth of neutralizability’, we
198 attempted a linear scale conversion of the neutralizing titer by modifying previously
199 employed methods [15]. Briefly, the neutralizing titer [IU/mL] of each convalescent sample
200 was computed from their %inhibition values [%], through interpolation from standard curves
201 that were generated by testing serially-diluted WHO International Standard (20/136) sera
202 (Figure 3, panel A). The ‘breadth of neutralizability’ was expressed as the NT against the
203 Alpha, Delta, and Omicron VOC RBDs (NT_{Alpha} , NT_{Delta} , and NT_{Omicron} , respectively) relative
204 to the NT against the WT RBD (NT_{WT}) in fold changes. Interestingly, when NTs against
205 SARS-CoV-2 VOCs were plotted against that of WT, with respect to the serum antibody’s
206 AI, sera of higher AIs tended to show higher NT_{Alpha} , NT_{Delta} , and NT_{Omicron} values relative to

207 NT_{WT} (Figure 3, panel B). Next, the fold change in NT against SARS-CoV-2 VOCs relative
208 to the WT was compared between low- (below the 50th percentile) and high-avidity (50th
209 percentile and above) serum samples. Higher-avidity sera showed greater fold change in
210 NT across the different SARS-CoV-2 VOCs (Figure 3, panel C). Altogether, the results
211 indicated that sera of higher AIs exhibited enhanced breadth of neutralizability and better
212 tolerated the variations in SARS-CoV-2 RBD.

213

214 **Vaccinees experience lesser extent of antibody maturation compared with**
215 **convalescents**

216 The variable kinetics of serum antibody avidity maturation between natural
217 infection immunity and vaccine-elicited immune responses were assessed through analysis
218 of sera from recipients of the BNT162b2 SARS-CoV-2 mRNA vaccine (vaccinees). Sera
219 collected from vaccinees at week 3 (n = 9) and week 25 (n = 8) after the first dose were
220 matched for their total anti-spike IgG titers (median OD₄₅₀ 1.37 (IQR 1.23–1.90) vs. 1.48
221 (IQR 1.20–1.75), $p = 1.0$), and their AIs were further compared with those of convalescent
222 individuals (Figure 4, panel A). Serum antibodies present in the sera of week-25 vaccinees
223 demonstrated significantly higher AIs compared with those of week-3 vaccinees (median
224 44.2 (IQR 38.3–47.4) vs 23.4 (IQR 16.9–26.6), $p = 0.0002$), indicating that the second dose

225 of the vaccine had boosted the hosts' maturation of antibody avidity. However, the AIs of
226 week-25 (approximate month 6) vaccinees were still only equivalent to those of month-2
227 early-convalescents, depicting a substantial lag in the avidity maturation process unique to
228 the vaccine-elicited immune response (Figure 4, panel B).

229

230 **Contribution of the matured IgG fraction to neutralizability among vaccinees**

231 Interestingly, in contrast to the convalescent sera and the week-25 vaccinee sera,
232 the neutralizability of the sera of week-3 vaccinees showed a relatively weak correlation
233 (Spearman's $r = 0.52$, $p = 0.16$) with their urea-resistant anti-spike IgG titer. The correlation
234 was rather strong (Spearman's $r = 0.87$, $p < 0.01$) when the levels of neutralizability were
235 plotted against total anti-spike IgG titers. This indicates that high-avidity antibodies
236 contribute less to neutralizability early in the vaccine response and become a stronger
237 determinant only after the second dose (Spearman's $r = 0.71$, $p = 0.06$). Reflecting their still
238 insufficient degree of maturation, the breadth of neutralizability of the week-25 vaccinees'
239 sera was limited to an extent comparable to that of early-convalescent sera (Figure 4, panel
240 C).

241

242 **Discussions**

243 Antibody avidity maturation in COVID-19 convalescents was observed as an
244 ongoing process that surprisingly extended months beyond the acute phase. This finding
245 supports the notion that SARS-CoV-2 proteins persist in tissues to continuously fuel the
246 germinal centers for antigen presentation, even during late convalescence [19]. More
247 importantly, the high-avidity neutralizing IgGs, which are the result of continuous B-cell
248 evolution, remain in the circulation of late convalescents, fortifying for viral re-encounters by
249 exerting enhanced cross-neutralizability against emerging SARS-COV-2 variants.

250 In theory, immature plasma cells produce antibodies that possess
251 conformationally flexible antigen-binding surfaces, which at the cost of lowered specificity
252 and affinity, are capable of recognizing diverse antigens (poly-reactivity hypothesis) [20]. In
253 contrast, mature plasma cells produce antibodies of preorganized and rigid paratopes so
254 as to take more energetically favorable configurations with improved complementarity
255 against epitopes [21]. This general tendency towards paratope rigidification upon avidity
256 maturation, while favorable in terms of enhancing specificity, is seemingly detrimental for
257 broad cross-reactivity. In the case of SARS-CoV-2-neutralizing antibodies, however, our
258 results show that high-avidity antibodies exert broader protection against evolving variants,
259 granting long-lasting protective immunity. This paradoxical relationship between affinity
260 maturation and the broadening in reactivity of SARS-CoV-2-neutralizing antibodies is

261 worthy of note. The molecular basis of B-cell evolution is explained by the acquisition of
262 somatic hypermutations [22]. The aforementioned rigidification of paratopes is only one
263 possible consequence of such somatic hypermutations. Mutations may lead to increased
264 buried surface area upon complex formation, strengthening antibody-antigen binding. B-
265 cells may alternatively acquire amino acid substitutions that result in better complementarity
266 of the antigen binding site. Additive molecular contacts at the paratope-epitope interface,
267 through the addition of novel polar or hydrophobic bonds, may also underlie the better
268 complementarity [23]. The increase in variety of the structural determinants shall decrease
269 the dependency of the paratope-epitope interaction on specific amino acid residues [24].
270 Thus, the latter diverse biophysical mechanisms of antibody affinity maturation all provide
271 explanations to the tolerability of high-affinity antibodies against SARS-CoV-2 variants.

272 Given that the majority of the world's population has relied largely on the SARS-
273 CoV-2 vaccines for immunological protection, our secondary interest was how the vaccine-
274 elicited immune responses were different from natural infection-acquired immunity. The
275 kinetics of affinity maturation of SARS-CoV-2-specific antibodies have recently been shown
276 to correlate with the longevity of immune protection following natural SARS-CoV-2 infection
277 [25–27]. The here observed higher potency of the high-avidity antibodies in neutralizing
278 SARS-CoV-2 may counter the longitudinal decay in quantity and explain the durability of

279 infection-acquired immune protection. Interestingly, compared with natural infection, we
280 observed a substantial delay in the maturation process of vaccine-elicited antibodies. This
281 was accompanied by still insufficient cross-neutralizability against SARS-CoV-2 variants
282 even 6 months after vaccination. Large-scale clinical trials in real-world settings have
283 shown greater protection associated with infection-acquired immunity than with vaccine-
284 elicited immune responses [28,29]. The present study further enriches the evidence for and
285 provides an immunological basis to the greater protection associated with infection-
286 acquired immunity. Additionally, the urea-resistant fraction of the antibody titer was
287 predictive of neutralizability only following the second dose of the vaccine. In contrast to the
288 limited variety of epitopes recurrently targeted across convalescent individuals [30], the
289 vaccine-elicited immune response is mapped to a broadened epitope landscape [31,32].
290 During the initial response to the SARS-CoV-2 vaccine, the majority of urea-resistant
291 signals obtained from our avidity ELISA were possibly from a widely dispersed, non-
292 neutralizing antibody repertoire that still dominated the week-3 vaccinees' sera. The second
293 vaccine dose seemingly facilitated the positive selection of neutralizing over non-
294 neutralizing epitopes. Collectively, the dynamics of epitope selection, as well as avidity
295 maturation, seem to radically differ among vaccinees and convalescents [33].

296 Furthermore, circulating IgG may serve as sources of passive

297 immunotherapeutics [34]. In such a context, their extent of maturity may affect cross-
298 neutralizability and immunotherapy outcome. Immunotherapy using convalescent sera has
299 unfortunately remained investigational for COVID-19, though expected beneficial for those
300 with deficient active immunity [35,36]. To mitigate the emergence of immune-escaping
301 variants in future pandemics, assessing avidity to stratify the potency of donated sera may
302 be a reasonable strategy for effective immunotherapy.

303 Limitations of the present study include: (i) the serum samples were not serial
304 collections from individuals, (ii) the cellular compartment was not studied, which also plays
305 decisive roles in immune protection, and (iii) the observation period of vaccinees was
306 limited, so the long-term consequences remain elusive.

307 In conclusion, the present study showed that the continuous process of avidity
308 maturation, extending beyond late convalescence, grants broader neutralizability and
309 robust protection that stand resilient against emerging SARS-CoV-2 variants. With
310 immunopotentialization through repeat vaccinations becoming a pivotal strategy to accomplish
311 herd immunity, understanding the longitudinal evolution of vaccine-induced immune
312 responses and the incremental protective effects of booster vaccinations, that are to be
313 also repeated in convalescent individuals ('hybrid immunity'), remains critical.

314

315 **Funding**

316 This research was supported by the Japan Agency for Medical Research and
317 Development [grant numbers JP20jk0110021 to Y.N., JP20wm0125003 and
318 JP20he1122001 to Y.K.]; the Japan Society for the Promotion of Science KAKENHI
319 [21K09078 to N.K., 22K15927 to Y.N.]; and the Osaka Metropolitan University Strategic
320 Research Grant [grant number OCU-SRG2021_YR09 to Y.N.]. The authors also received
321 support from the Osaka Metropolitan University Special Reserves Fund for COVID-19 and
322 the Shinya Yamanaka Laboratory COVID-19 Private Fund.

323

324 **Acknowledgments**

325 The authors would like to thank all participants of the study and, for technical
326 assistance, Mrs. Mika Oku from Osaka Metropolitan University. Data acquisition was partly
327 performed at the Research Support Platform, Graduate School of Medicine, Osaka
328 Metropolitan University.

329

330 **Conflicts of Interest**

331 Y.N. and Y.K. report equity ownership of Quantum Molecular Diagnostics, an
332 Osaka Metropolitan University spinout targeting infectious diseases to develop innovative

333 diagnostics. Y.N. and Y.K. also report receiving financial support outside of this work from

334 Abbott Japan LLC, Japan.

335

336 **References**

- 337 [1] Hacısuleyman E, Hale C, Saito Y, et al. Vaccine breakthrough infections with SARS-
338 CoV-2 variants. *N Engl J Med*, 2021;384:2212–2218.
339 <https://doi.org/10.1056/nejmoa2105000>.
- 340 [2] To KK-W, Hung IF-N, Ip JD, et al. Coronavirus Disease 2019 (COVID-19) Re-infection
341 by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain
342 confirmed by whole genome sequencing. *Clin Infect Dis*, 2020;2019:1–6.
343 <https://doi.org/10.1093/cid/ciaa1275>.
- 344 [3] Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly
345 predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med*,
346 2021;27:1205–1211. <https://doi.org/10.1038/s41591-021-01377-8>.
- 347 [4] Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 breakthrough infections in vaccinated
348 health care workers. *N Engl J Med*, 2021;385:1474–1484.
349 <https://doi.org/10.1056/nejmoa2109072>.
- 350 [5] Cromer D, Juno JA, Khoury D, et al. Prospects for durable immune control of SARS-
351 CoV-2 and prevention of reinfection. *Nat Rev Immunol*, 2021;21:395–404.
352 <https://doi.org/10.1038/s41577-021-00550-x>.
- 353 [6] Bauer G. The potential significance of high avidity immunoglobulin G (IgG) for protective

- 354 immunity towards SARS-CoV-2. *Int J Infect Dis*, 2021;106:61–64.
- 355 <https://doi.org/10.1016/j.ijid.2021.01.061>.
- 356 [7] Bauer G, Struck F, Schreiner P, Staschik E, Soutschek E, Motz M. The challenge of
357 avidity determination in SARS-CoV-2 serology. *J Med Virol*, 2021;93:3092–3104.
358 <https://doi.org/10.1002/jmv.26863>.
- 359 [8] Nakagama Y, Nitahara Y, Kaku N, Tshibangu-Kabamba E, Kido Y. A dual-antigen
360 SARS-CoV-2 serological assay reflects antibody avidity. *J Clin Microbiol*,
361 2022;60:e0226221. <https://doi.org/10.1128/JCM.02262-21>.
- 362 [9] Adachi T, Ayusawa M, Ujiie M, et al. Novel coronavirus infection COVID-19 medical
363 practice guidelines. Version 7.2. Available at:
364 <https://www.mhlw.go.jp/content/000936623.pdf> (accessed 1 July 2022).
- 365 [10] Nakagama Y, Komase Y, Candray K, et al. Serological testing reveals the hidden
366 COVID-19 burden among health care workers experiencing a SARS-CoV-2 nosocomial
367 outbreak. *Microbiol Spectr*, 2021;9:e0108221. [https://doi.org/10.1128/Spectrum.01082-](https://doi.org/10.1128/Spectrum.01082-21)
368 21.
- 369 [11] Nakagama Y, Rodriguez-Funes MV, Dominguez R, et al. Cumulative seroprevalence
370 among healthcare workers after the first wave of the COVID-19 pandemic in El Salvador,
371 Central America. *Clin Microbiol Infect*, 2022;S1198-743X(22)00333-0. doi:

- 372 10.1016/j.cmi.2022.06.020.
- 373 [12] Pichler D, Baumgartner M, Kimpel J, et al. Marked increase in avidity of SARS-CoV-2
374 antibodies 7–8 months after infection is not diminished in old age. *J Infect Dis*, 2021;1–7.
375 <https://doi.org/10.1093/infdis/jiab300>.
- 376 [13] Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based
377 on antibody-mediated blockage of ACE2–spike protein–protein interaction. *Nat*
378 *Biotechnol*, 2020;38:1073–1078. <https://doi.org/10.1038/s41587-020-0631-z>.
- 379 [14] Mariën J, Michiels J, Heyndrickx L, et al. Evaluation of a surrogate virus neutralization
380 test for high-throughput serosurveillance of SARS-CoV-2. *J Virol Methods*,
381 2021;297:114228. <https://doi.org/10.1016/j.jviromet.2021.114228>.
- 382 [15] Taylor SC, Hurst B, Martiszus I, et al. Semi-quantitative, high throughput analysis of
383 SARS-CoV-2 neutralizing antibodies: Measuring the level and duration of immune
384 response antibodies post infection/vaccination. *Vaccine*, 2021;39:5688–5698.
385 <https://doi.org/10.1016/j.vaccine.2021.07.098>.
- 386 [16] National Institute for Biological Standards and Control. First WHO International Standard
387 for anti-SARS-CoV-2 immunoglobulin, human. (NIBSC code: 20/136) Available at:
388 <https://www.nibsc.org/documents/ifu/20-136.pdf> (accessed 1 July 2022).
- 389 [17] Moriyama S, Adachi Y, Sato T, et al. Temporal maturation of neutralizing antibodies in

- 390 COVID-19 convalescent individuals improves potency and breadth to circulating SARS-
391 CoV-2 variants. *Immunity*, 2021;54:1841-1852.e4.
392 <https://doi.org/10.1016/j.immuni.2021.06.015>.
- 393 [18] Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2.
394 *Nature*, 2021;591:639–644. <https://doi.org/10.1038/s41586-021-03207-w>.
- 395 [19] Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2.
396 *Nature*, 2021;591:639–644. <https://doi.org/10.1038/s41586-021-03207-w>.
- 397 [20] Furukawa K, Akasako-Furukawa A, Shirai H, Nakamura H, Azuma T. Junctional amino
398 acids determine the maturation pathway of an antibody. *Immunity*, 1999;11:329–338.
399 [https://doi.org/10.1016/S1074-7613\(00\)80108-9](https://doi.org/10.1016/S1074-7613(00)80108-9).
- 400 [21] Manivel V, Sahoo NC, Salunke DM, Rao KVS. Maturation of an antibody response is
401 governed by modulations in flexibility of the antigen-combining site. *Immunity*,
402 2000;13:611–620. [https://doi.org/10.1016/S1074-7613\(00\)00061-3](https://doi.org/10.1016/S1074-7613(00)00061-3)
- 403 [22] Victora GD, Nussenzweig MC. Germinal centers. *Annu Rev Immunol*, 2012;30:429–457.
404 <https://doi.org/10.1146/annurev-immunol-020711-075032>
- 405 [23] Mishra AK, Mariuzza RA. Insights into the structural basis of antibody affinity maturation
406 from next-generation sequencing. *Front Immunol*, 2018;9:117.
407 <https://doi.org/10.3389/fimmu.2018.00117>.

- 408 [24] Muecksch F, Weisblum Y, Barnes CO, et al. Affinity maturation of SARS-CoV-2
409 neutralizing antibodies confers potency, breadth, and resilience to viral escape
410 mutations. *Immunity*, 2021;54:1853-1868.e7.
411 <https://doi.org/10.1016/j.immuni.2021.07.008>.
- 412 [25] Luo YR, Chakraborty I, Yun C, Wu AHB, Lynch KL. Kinetics of severe acute respiratory
413 syndrome coronavirus 2 (SARS-CoV-2) antibody avidity maturation and association with
414 disease severity. *Clin Infect Dis*, 2021;73:e3095–e3097.
415 <https://doi.org/10.1093/cid/ciaa1389>.
- 416 [26] Löfström E, Eringfält A, Kötz A, et al. Dynamics of IgG-avidity and antibody levels after
417 Covid-19. *J Clin Virol*, 2021;144:104986. <https://doi.org/10.1016/j.jcv.2021.104986>.
- 418 [27] Chia WN, Zhu F, Ong SWX, et al. Dynamics of SARS-CoV-2 neutralising antibody
419 responses and duration of immunity: a longitudinal study. *Lancet Microbe*, 2021;2:e240–
420 e249. [https://doi.org/10.1016/S2666-5247\(21\)00025-2](https://doi.org/10.1016/S2666-5247(21)00025-2).
- 421 [28] Gazit S, Shlezinger R, Perez G, et al. Severe acute respiratory syndrome coronavirus 2
422 (SARS-CoV-2) naturally acquired immunity versus vaccine-induced immunity,
423 reinfections versus breakthrough infections: a retrospective cohort study. *Clin Infect Dis*,
424 2022;2:1–7. <https://doi.org/10.1093/cid/ciac262>.
- 425 [29] Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after Covid-19


- 426 vaccination and previous infection. *N Engl J Med*, 2022;386:1207–1220.
- 427 <https://doi.org/10.1056/nejmoa2118691>.
- 428 [30] Tong P, Gautam A, Windsor IW, et al. Memory B cell repertoire for recognition of
429 evolving SARS-CoV-2 spike. *Cell*, 2021:1–12. <https://doi.org/10.1016/j.cell.2021.07.025>.
- 430 [31] Nitahara Y, Nakagama Y, Kaku N, et al. High-resolution linear epitope mapping of the
431 receptor binding domain of SARS-CoV-2 spike protein in COVID-19 mRNA vaccine
432 recipients. *Microbiol Spectr*, 2021;9 e0096521. [https://doi.org/10.1128/spectrum.00965-](https://doi.org/10.1128/spectrum.00965-21)
433 21.
- 434 [32] Greaney AJ, Loes AN, Gentles LE, et al. Antibodies elicited by mRNA-1273 vaccination
435 bind more broadly to the receptor binding domain than do those from SARS-CoV-2
436 infection. *Sci Transl Med*, 2021;13:1–13. <https://doi.org/10.1126/scitranslmed.abi9915>.
- 437 [33] Wang Z, Muecksch F, Schaefer-Babajew D, et al. Naturally enhanced neutralizing
438 breadth against SARS-CoV-2 one year after infection. *Nature*, 2021;595:426–431.
439 <https://doi.org/10.1038/s41586-021-03696-9>.
- 440 [34] Tang J, Lee Y, Ravichandran S, et al. Epitope diversity of SARS-CoV-2 hyperimmune
441 intravenous human immunoglobulins and neutralization of variants of concern. *iScience*,
442 2021;24:103006. <https://doi.org/10.1016/j.isci.2021.103006>.
- 443 [35] Takakuwa T, Nakagama Y, Yasugi M, et al. Discrepant antigen-specific antibody

444 responses causing SARS-CoV-2 persistence in a patient receiving B-cell-targeted
445 therapy with rituximab. Intern Med, 2021;60:3827–3831.
446 <https://doi.org/10.2169/internalmedicine.7884-21>.
447 [36] Takita M, Yoshida T, Tsuchida T, et al. Low SARS-CoV-2 antibody titers may be
448 associated with poor clinical outcomes for patients with severe COVID-19. Sci Rep,
449 2022;12:9147. <https://doi.org/10.1038/s41598-022-12834-w>.
450

451 **Figure legends**

452


453 (A)



454

455


456 (B)



457

458

459 (C)



460

461

462 Figure 1. Evolution of anti-SARS-CoV-2 IgG in convalescent individuals. A) Anti-spike IgG

463 levels of individuals observed across the convalescent phase, and their linear fit (solid red

464 line) with 95% confidence intervals (dashed red lines). B) Resistance of the OD₄₅₀ signal

465 against urea treatment in subsets of sera from early- (n = 29) and late-convalescent (n =


466 26) samples, matched by total anti-spike IgG titers. C) Avidity index of antibodies present in

467 early- (n = 29) and late-convalescent (n = 26) sera. OD₄₅₀, optical density at 450 nm.

468 Statistical significance: **** $p < 0.0001$.

469


470 (A)



471

472

473 (B)



474

475

476 Figure 2. Central role of high-avidity IgG in neutralizing SARS-CoV-2.

477 A) Neutralizability of antibodies present in early- (n = 29) and late-convalescent sera (n =

478 26) against wild-type and variant SARS-CoV-2, as measured by surrogate virus

479 neutralization, and plotted against total (upper) and urea-resistant, high-avidity anti-spike


480 IgG titers (lower). B) Resistance of SARS-CoV-2 variants against neutralization by

481 convalescent sera. OD₄₅₀, optical density at 450 nm. Statistical significance: *** $p < 0.001$,

482 **** $p < 0.0001$.

483


484 (A)



485

486


487 (B)



488

489

490 (C)




491

492

493 Figure 3. Enhanced neutralization breadth of higher-avidity anti-SARS-CoV-2 IgG.
494 A) Four-parameter logistic standard curves for conversion of inhibition rates to neutralizing
495 antibody titers in WHO International Standard units, IU/mL. B) Cross-neutralizability of
496 convalescent sera against the Alpha (left), Delta (middle), and Omicron variants (right). The
497 samples' avidity indices are depicted according to the color scale shown. C) Relative
498 inhibition potency towards SARS-CoV-2 variants indexed to the wild-type neutralizing titer,
499 indicating the breadth of neutralizability per serum. Statistical significance: ** $p < 0.01$, *** p
500 < 0.001 .
501


502 (A)



503

504


505 (B)



506

507

508 (C)









509




510



511 Figure 4. Functional evolution of anti-SARS-CoV-2 IgG in recipients of the BNT162b2
512 SARS-CoV-2 mRNA vaccine.

513 A) Resistance of the OD₄₅₀ signal against urea treatment in subsets of sera from vaccine
514 recipients at week 3 (n = 9) and week 25 (n = 8) post-vaccination, matched by total anti-
515 spike IgG titers. B) Avidity index of antibodies present in week-3 (n = 9) and week-25 (n =
516 8) vaccinees in comparison with convalescent individuals. C) Relative inhibition potency of
517 week-25 vaccinee sera (n = 8) towards SARS-CoV-2 variants plotted against that of
518 convalescent individuals. OD₄₅₀, optical density at 450 nm. Statistical significance: *p <
519 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

(A)**(B)****(C)**

(A)**Total IgG****High-avidity IgG****(B)**



(A)**(B)****(C)**